A smartphone app for bladder cancer patients
The iBlad App - a National, Exploratory Study on a Multimodality Smartphone App in Bladder Cancer for Better Understanding of Symptoms, Quality of Life and Need for Supportive Care
This study is testing a new smartphone app for bladder cancer patients to help them track their symptoms and connect with others while getting feedback on how well it works for them.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | Odense University Hospital Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 2 sites (Copenhagen and 1 other locations) |
| Trial ID | NCT05710159 on ClinicalTrials.gov |
What this trial studies
This project aims to develop and implement a national multimodality smartphone application for patients with bladder cancer, building on insights from the iBLAD study. The app will include patient-reported outcome (PRO) questions regarding symptoms and quality of life, as well as information for healthcare providers and peer-to-peer advice. The usability and patient satisfaction with the app will be evaluated using qualitative methods. Patients will receive weekly electronic questionnaires to monitor their symptoms and side effects throughout their treatment.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with bladder cancer undergoing standard therapy who can read Danish.
Not a fit: Patients without a smartphone or those with serious cognitive impairments may not benefit from this study.
Why it matters
Potential benefit: If successful, this app could enhance symptom management and quality of life for bladder cancer patients.
How similar studies have performed: Other studies have shown success with similar digital health interventions, indicating potential for positive outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with bladder cancer defined as both urothelial tract-, bladder- and urethral cancer initiating first or second-line standard therapy with either chemotherapy or immunotherapy * Age ≥ 18 years, * Performance status ≤ 2 * Ability to read Danish * No serious cognitive impairment * Informed consent. Exclusion Criteria: * No smartphone, * Dementia, mental alteration, or psychiatric disease that can compromise informed consent from the patient and/or adherence to the protocol and the monitoring of the trial.
Where this trial is running
Copenhagen and 1 other locations
- Rigshospitalet — Copenhagen, Denmark (Not_yet_recruiting)
- Odense University Hospital — Odense, Denmark (Recruiting)
Study contacts
- Principal investigator: Helle Pappot, Professor — Rigshospitalet, Denmark
- Study coordinator: Helle Pappot, Professor
- Email: helle.pappot@regionh.dk
- Phone: + 45 35454089
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.